Format

Send to:

Choose Destination
See comment in PubMed Commons below
Z Rheumatol. 2008 Oct;67(6):491-8; quiz 499. doi: 10.1007/s00393-008-0344-z.

[Lupus erythematodes--evidence-based recommendations for monitoring and therapy].

[Article in German]

Author information

  • 1Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf.

Abstract

Standard care of patients with systemic lupus erythematosus (SLE) covers continuous extended diagnostics including the search for new disease manifestations, evaluation of disease activity and of comorbidities requiring treatment and, in particular, accompanying infections. Immunosuppressive medication is determined by active organ manifestations and global disease activity, which is measured by standardized scores. In this context, it is important to differentiate between activity and damage, since damage is mostly treated symptomatically and, by definition, cannot be changed by immunosuppression. Activity and damage are the keystones estimating prognosis, especially since validated surrogate markers are lacking. The standard forms of immunosuppressive therapy for SLE have not changed in recent years, but the strategies are new. Antimalarials are indicated in every lupus patient as long as there are no contraindications. In proliferative nephritis, cyclophosphamide should be limited to the induction phase.

PMID:
18777026
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk